Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

帕博西利布 富维斯特朗 医学 转移性乳腺癌 内科学 危险系数 乳腺癌 无进展生存期 癌症 肿瘤科 化疗 安慰剂 妇科 三苯氧胺 置信区间 病理 替代医学
作者
Nicholas C. Turner,Fabrice André,M Cristofanilli,Sunil Verma,Hiroji Iwata,Sherene Loi,Nadia Harbeck,Jai Youl Ro,Marco Colleoni,Kai Zhang,C Huang Bartlett,C. Giorgetti,DJ Slamon
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:77 (4_Supplement): P4-06 被引量:10
标识
DOI:10.1158/1538-7445.sabcs16-p4-22-06
摘要

Abstract Background: Palbociclib (PAL) plus fulvestrant (FUL) demonstrated significant improvement in progression-free survival (PFS) vs placebo (PBO) plus FUL in women with HR+/HER2- advanced breast cancer (ABC) whose disease had progressed on prior endocrine therapy (ET). Because the effectiveness of standard therapies after progression on PAL is unknown, it is important to understand whether the benefits of PAL with respect to PFS extend to subsequent treatments. Method: Pre-, peri-, and postmenopausal patients (pts) with HR+/HER2- ABC who had relapsed/progressed on prior ET were randomized 2:1 to PAL (125 mg/d oral [3 wk on drug, 1 wk off]) + FUL (500 mg/mo intramuscular, per standard of care) or PBO+FUL. One prior line of chemotherapy (CT) for ABC was allowed. For 9 mo immediately after participation in PALOMA-3, pts were assessed every 3 mo for information on poststudy progression and treatment; the type of treatment, its duration, and sites of progression were analyzed. Results: As of Oct 2015, with a median follow-up of 15.8 mo for PAL+FUL and 15.3 mo for PBO+FUL, 333 PFS events were observed (200 and 133, respectively). Median PFS was 11.2 vs 4.6 mo (hazard ratio [HR], 0.497 [95% CI, 0.398–0.620]; P<0.0001). In both treatment arms, the most common sites of disease progression were the liver (149 [43%] and 94 [54%]) and bone (55 [16%] and 43 [25%]). 1 pt in each treatment arm developed new brain metastasis. The most commonly used postprogression regimens were capecitabine (n=57 [28.8%]), paclitaxel (n=22 [11.1%]), and exemestane (n=34 [17.2%]). Median time to subsequent CT (from randomization to the start of the first CT treatment poststudy) was longer with PAL+FUL (252 d) than with PBO+FUL (132 d). This was also observed in pts with visceral disease who never received CT in the advanced setting at study entry (median 208 and 125 d, respectively). 252 pts had subsequent disease progression, treatment discontinuation on immediate subsequent therapy, or died. Proportionally fewer pts in the PAL+FUL vs PBO+FUL arm discontinued next-line treatment (33% vs 46%), indicating that PAL does not adversely affect the efficacy of subsequent treatments. Analysis of the time to end of next-line treatment showed that the HR between the 2 treatment arms was 0.623 ([95% CI, 0.482–0.805]; 1-sided P value=0.0001) in favor of PAL treatment (Table 1). Conclusion: The current analysis demonstrated that the treatment effect of PAL+FUL was retained in the most immediate line postprogression and that progression after PAL has no effect on the therapeutic benefit from subsequent treatments. Sponsor: Pfizer Table 1. PAL+FUL (n=347)PBO+FUL (n=174)Pts who progressed and were eligible for subsequent therapy, n (%)198 (57)130 (75)Pt with postprogression event, n (%)156 (45)96 (55)Objective progression on next-line therapy, n (%)15 (4)5 (3)Deaths, n (%)28 (8)11 (6)End of next-line therapy, n (%)113 (33)80 (46)Median (95% CI) probability of being event-free at 12 mo69.2 (64.0–73.8)54.4 (46.4–61.7)Median (95% CI) time to end of next-line therapy, mo17.9 (16.0–NR)12.8 (11.0–14.6)Hazard ratio (95% CI)0.623 (0.482–0.805)P value0.0001FUL=fulvestrant; NR=not reached; PAL=palbociclib; PBO=placebo. Citation Format: Turner NC, André F, Cristofanilli M, Verma S, Iwata H, Loi S, Harbeck N, Ro J, Colleoni M, Zhang K, Huang Bartlett C, Giorgetti C, Slamon D. Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-06.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
something完成签到,获得积分10
刚刚
Yee完成签到,获得积分10
1秒前
2秒前
可可发布了新的文献求助10
2秒前
传奇3的应助被木木采纳,获得10
2秒前
orixero的应助被pepsi191采纳,获得10
2秒前
2秒前
英姑的应助被乐观蛋挞采纳,获得10
3秒前
3秒前
4秒前
zwhy发布了新的文献求助10
4秒前
小雪发布了新的文献求助10
4秒前
4秒前
4秒前
4秒前
火火发布了新的文献求助10
4秒前
5秒前
5秒前
5秒前
姜茂强发布了新的文献求助10
5秒前
6秒前
6秒前
zws的应助被小灰狼采纳,获得10
6秒前
7秒前
烟花完成签到,获得积分10
7秒前
7秒前
JamesPei的应助被西楼采纳,获得10
7秒前
英姑的应助被一颗山芋采纳,获得10
8秒前
8秒前
asheng发布了新的文献求助30
8秒前
guan发布了新的文献求助10
8秒前
张境文发布了新的文献求助10
8秒前
涵泽发布了新的文献求助10
8秒前
归途完成签到,获得积分10
9秒前
仁爱惜灵完成签到,获得积分10
10秒前
ssss发布了新的文献求助10
10秒前
今后的应助被xushanqi采纳,获得10
11秒前
小二郎的应助被清风采纳,获得10
11秒前
yangg发布了新的文献求助10
11秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171556
求助须知:如何正确求助?哪些是违规求助? 9564290
关于积分的说明 21774363
捐赠科研通 7763124
什么是DOI,文献DOI怎么找? 3430998
关于科研通互助平台的介绍 2554820
邀请新用户注册赠送积分活动 2475918